bupropione

Developed for: dysthymic disorder · major depressive disorder
Investigated by: Centre for Addiction and Mental Health · Nova Scotia Health Authority · Queen's University · University Health Network, Toronto

today NCT02752542 · Ph 4

20172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT02752542	Oct 2016 → Jun 2026 overdue	dysthymic disorder, major depressive disorder	Nova Scotia Health Authority	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	bupropione	“Augmentation (aripiprazole 2-10mg, bupropione 150-450mg) will be offered to participants with partial response.” NCT02752542 ↗